1 FEV1 (% predicted) |
7 |
195 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.33 [‐7.89, ‐0.77] |
1.1 MDI |
2 |
72 |
Mean Difference (IV, Fixed, 95% CI) |
‐6.0 [‐13.09, 1.09] |
1.2 MDI+SPACER |
2 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.62 [‐10.26, 1.03] |
1.3 DPI |
3 |
63 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.79 [‐8.83, 3.24] |
2 FEV1(litres) |
4 |
103 |
Mean Difference (IV, Fixed, 95% CI) |
0.07 [‐0.25, 0.40] |
2.1 MDI |
1 |
30 |
Mean Difference (IV, Fixed, 95% CI) |
0.41 [‐0.40, 1.22] |
2.2 MDI+SPACER |
1 |
28 |
Mean Difference (IV, Fixed, 95% CI) |
0.24 [‐0.23, 0.71] |
2.3 DPI |
2 |
45 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.30 [‐0.84, 0.24] |
3 Change in FEV1 (litres) compared to baseline |
2 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.20 [‐0.33, ‐0.07] |
3.1 MDI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.2 MDI+SPACER |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
3.3 DPI |
2 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.20 [‐0.33, ‐0.07] |
4 Morning PEFR (L/min) |
3 |
94 |
Mean Difference (IV, Fixed, 95% CI) |
‐30.86 [‐66.51, 4.79] |
4.1 MDI |
1 |
46 |
Mean Difference (IV, Fixed, 95% CI) |
‐34.0 [‐88.62, 20.62] |
4.2 MDI+SPACER |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
‐28.0 [‐86.82, 30.82] |
4.3 DPI |
1 |
17 |
Mean Difference (IV, Fixed, 95% CI) |
‐29.46 [‐107.88, 48.96] |
5 Change in morning PEFR (L/min) compared to baseline |
6 |
469 |
Mean Difference (IV, Fixed, 95% CI) |
‐28.92 [‐36.11, ‐21.74] |
5.1 MDI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
5.2 MDI+SPACER |
3 |
136 |
Mean Difference (IV, Fixed, 95% CI) |
‐42.09 [‐60.18, ‐24.00] |
5.3 DPI |
3 |
333 |
Mean Difference (IV, Fixed, 95% CI) |
‐26.45 [‐34.29, ‐18.62] |
6 Change in evening PEFR (L/min) compared to baseline |
6 |
469 |
Mean Difference (IV, Fixed, 95% CI) |
‐20.64 [‐28.29, ‐13.00] |
6.1 MDI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
6.2 MDI+SPACER |
3 |
136 |
Mean Difference (IV, Fixed, 95% CI) |
‐31.54 [‐45.39, ‐17.69] |
6.3 DPI |
3 |
333 |
Mean Difference (IV, Fixed, 95% CI) |
‐15.88 [‐25.04, ‐6.71] |
7 Change in daytime use of short‐acting beta2 agonist (puffs/daytime) compared to baseline |
5 |
480 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.43 [‐0.80, ‐0.06] |
7.1 MDI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
7.2 MDI+SPACER |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.0 [‐4.96, ‐1.04] |
7.3 DPI |
4 |
409 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.34 [‐0.71, 0.03] |
8 Change in night‐time use of short‐acting beta2 agonist compared to baseline (puffs/night) |
3 |
304 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.71 [‐1.09, ‐0.33] |
8.1 MDI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
8.2 MDI+SPACER |
1 |
71 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.3 [‐3.55, ‐1.05] |
8.3 DPI |
2 |
233 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.54 [‐0.95, ‐0.14] |
9 Methacholine bronchial responsiveness (log 10 values) |
2 |
54 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.12 [‐0.48, 0.23] |
9.1 MDI |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.14 [‐0.60, 0.32] |
9.2 MDI+SPACER |
1 |
28 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.10 [‐0.65, 0.45] |
9.3 DPI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
10 Histamine bronchial responsiveness (log 10 values) |
2 |
80 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐0.70, ‐0.11] |
10.1 MDI |
1 |
49 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.53 [‐2.75, 1.69] |
10.2 MDI+SPACER |
1 |
31 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.40 [‐0.70, ‐0.10] |
10.3 DPI |
0 |
0 |
Mean Difference (IV, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
11 Withdrawal due to asthma exacerbation (No. of patients) |
17 |
910 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.17 [0.09, 0.33] |
11.1 MDI |
2 |
144 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.12 [0.04, 0.36] |
11.2 MDI+SPACER |
6 |
237 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.2 [0.01, 3.92] |
11.3 DPI |
9 |
529 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.22 [0.09, 0.53] |
12 Requirement for one or more courses of oral steroid for asthma exacerbation (No. of patients) |
5 |
255 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.25 [0.13, 0.48] |
12.1 MDI |
1 |
116 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.20 [0.09, 0.44] |
12.2 MDI+SPACER |
2 |
72 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.24 [0.05, 1.26] |
12.3 DPI |
2 |
67 |
Peto Odds Ratio (Peto, Fixed, 95% CI) |
0.55 [0.13, 2.28] |
13 Oropharyngeal side effects (No. of patients) |
5 |
275 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.81 [0.53, 1.23] |
13.1 MDI |
1 |
116 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.55 [0.30, 1.00] |
13.2 MDI+SPACER |
2 |
103 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.64 [0.32, 1.29] |
13.3 DPI |
2 |
56 |
Risk Ratio (M‐H, Fixed, 95% CI) |
5.90 [1.14, 30.62] |